Viatris Inc.

VTRSsupplier

Viatris is a global pharmaceutical company formed from the 2020 merger of Mylan and Pfizer's Upjohn division, focused on expanding access to generic and biosimilar medicines worldwide.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($15.0B)

Data statis (memuat keuangan langsung…)

Developed Markets (45%)

Emerging Markets (30%)

Greater China (12%)

JANZ (Japan, Australia, NZ) (13%)

Komposisi segmen dan pelanggan utama

Detail produk

Branded Generics35%

Off-patent branded drugs sold primarily in emerging markets

Complex Generics & Biosimilars25%

Biosimilar versions of Humira, Herceptin, and complex injectables

Generic Pharmaceuticals25%

Standard generic drugs for developed markets

Legacy Brands (Lipitor, EpiPen)15%

Heritage branded products from Pfizer Upjohn and Mylan

Hubungan Rantai Pasok

Mitra

Pfizer Inc.

Legacy Pfizer Upjohn product portfolio

Dampak: Medium — spun off from Pfizer

Pesaing

AbbVie Inc.

Biosimilar Humira competition

Dampak: Medium — biosimilar erosion of Humira

Pelanggan Utama

Walgreens Boots Alliance

Generic drug retail distribution

Dampak: Medium — pharmacy channel

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Viatris Inc..

Info Perusahaan

Kantor Pusat

Canonsburg, Pennsylvania, USA

Didirikan

2020

Karyawan

37,000+

Situs Web

viatris.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor